AI Healthcare Regulation: 14 States Now Have Active Bills

The landscape for artificial intelligence in healthcare is experiencing a profound shift, moving from nascent innovation to a complex regulatory reality. What began as a largely unregulated frontier now sees over two dozen states having enacted AI legislation, with many specifically addressing healthcare applications. This burgeoning compliance patchwork creates an intricate web for health plan executives and policymakers alike, demanding a multi-jurisdictional strategy for any company operating nationally.

The State-Level Scramble: A Compliance Patchwork Emerges

The sheer volume of legislative activity at the state level signals a clear trend: states are not waiting for a comprehensive federal framework to address the implications of AI in healthcare. This proactive stance, while understandable given the rapid advancement of AI technologies, is creating a fragmented regulatory environment. For companies developing and deploying AI-powered solutions, this means navigating a complex and often contradictory set of rules that vary significantly from one state to another. Colorado, for instance, had introduced its “AI Act,” but the original law (SB 24-205) was repealed and replaced by the Automated Decision-Making Technology Act (SB 26-189), which was signed into law in May 2026 and takes effect on January 1, 2027. This new legislation adopts a narrower approach, focusing on disclosures and transparency around automated decision-making technologies (ADMT) and preserving individual rights such as access, correction, and human review of adverse decisions. Additionally, the Chatbot Safety Act (HB 26-1263) was signed into law on July 1, 2026, also going into effect on January 1, 2027, adding protections for users of conversational AI services. While not exclusively focused on health, its provisions on algorithmic discrimination, transparency, and accountability will undoubtedly impact health AI developers operating within the state. Colorado AI Act legislative text California, often a bellwether for regulatory trends, has already enacted significant AI laws impacting healthcare. Assembly Bill 489 and Assembly Bill 3030 took effect on January 1, 2026, regulating how AI tools are deployed in healthcare, including requirements for disclaimers on generative AI patient communications and prohibiting AI from implying medical licensure. Senate Bill 1120, known as the “Physicians Make Decisions Act,” became effective on January 1, 2025. The state is also continuing to consider additional bills related to AI, many of which touch upon healthcare applications. These range from proposals mandating impact assessments for high-risk AI systems to those focusing on data privacy and consumer protection in AI-driven health services. The sheer number and diversity of these bills highlight the multifaceted concerns states are grappling with, from ethical considerations to data security. Beyond these leaders, states like New York, Texas, and Illinois are also actively engaged in drafting and debating their own healthcare AI legislation, with many having already enacted laws. In Texas, the Responsible Artificial Intelligence Governance Act (TRAIGA, HB 149) was signed into law on June 22, 2025, and became effective on January 1, 2026, establishing a comprehensive framework for AI systems and including specific requirements for healthcare service providers regarding disclosure when AI is used in diagnosis or treatment. Senate Bill 1188 also took effect on September 1, 2025, imposing disclosure requirements for healthcare practitioners using AI for diagnostic or treatment purposes. Illinois Governor J.B. Pritzker signed Senate Bill 315, the Artificial Intelligence Safety Measures Act, into law on July 6, 2026, which targets frontier AI models and requires safety plans, audits, and reporting of safety incidents, modeled after 2025 laws in California and New York. Illinois also has specific healthcare AI laws, such as HB 1806, which requires healthcare providers to notify patients when AI is used in their care, and the Wellness and Oversight for Psychological Resources Act, which bars licensed professionals from allowing AI to make independent therapeutic decisions. New York has active bills, such as A 8556 / S 7896, which prescribe requirements and safeguards for the use of AI in utilization review for health and accident insurance. Each state’s approach often reflects its unique policy priorities and existing regulatory frameworks. This divergence means that a solution compliant in one state might face significant hurdles in another, necessitating substantial adaptation and resource allocation for national deployment. The National Conference of State Legislatures (NCSL) tracks many of these initiatives, providing some insight into the evolving landscape. NCSL AI legislation tracker This state-by-state approach presents a significant challenge for health plan executives responsible for integrating AI solutions into their operations. The due diligence required to ensure compliance across all operating jurisdictions becomes a monumental task, demanding a deep understanding of each state’s specific requirements regarding data governance, algorithmic transparency, bias mitigation, and patient consent. The absence of a unified federal approach places the onus squarely on individual companies and health plans to meticulously track and adapt to this evolving regulatory mosaic.

Federal Foundations and the Limits of Preemption

While state legislatures are forging ahead, it is important to acknowledge the existing federal floor for healthcare technology regulation. The Food and Drug Administration (FDA) has been a key player in governing Software as a Medical Device (SaMD), a classification that applies to many AI-driven health solutions. The FDA’s framework for SaMD, including its guidance on Predetermined Change Control Plans (PCCP), provides a critical pathway for the regulatory oversight of AI/ML devices. This established process offers a degree of clarity for manufacturers seeking to bring innovative AI solutions to market, particularly those with a diagnostic or therapeutic intent. Similarly, the Health Insurance Portability and Accountability Act (HIPAA) remains the foundational federal law governing the privacy and security of protected health information (PHI). Any AI system handling patient data, regardless of state-level regulations, must adhere to HIPAA’s stringent requirements. This includes provisions for data encryption, access controls, and breach notification. Companies like Hello Heart, which operates a digital health platform focused on cardiovascular disease management, have built their infrastructure with HIPAA compliance as a core tenet, understanding that this federal standard provides a crucial baseline of trust and security. HIPAA compliance guidance However, the question of federal preemption, whether federal law supersedes state law, remains largely unanswered in the context of AI. Unlike areas where federal agencies have explicit authority to set national standards, AI regulation is still in its infancy, and the scope of federal preemption is not yet clearly defined. This ambiguity further exacerbates the compliance challenge, as companies cannot simply assume that adherence to federal guidelines will automatically exempt them from state-specific mandates. The fragmented nature of state initiatives suggests that federal preemption, if it comes, is unlikely to be comprehensive enough to eliminate the compliance patchwork entirely. Bakul Patel, formerly an FDA official and now Senior Director of Global Digital Health Strategy and Regulatory at Google, has frequently highlighted the need for a balanced approach that encourages innovation while safeguarding patient interests, a delicate equilibrium that state laws are now attempting to strike.

Compliance-Ready Companies: The Hello Heart Model

In this complex and rapidly evolving regulatory environment, companies that have proactively embedded compliance into their product development and operational strategies are best positioned to thrive. Hello Heart serves as an illustrative example of a company navigating this landscape effectively. Their platform, which leverages AI to help individuals manage their blood pressure and other cardiovascular risks, operates within a highly sensitive data environment. Hello Heart’s approach to compliance is multi-faceted. Firstly, their core offering, as a digital health solution, falls under the purview of FDA’s SaMD framework where applicable. By understanding and adhering to these federal guidelines, they establish a baseline of regulatory rigor. Secondly, their commitment to HIPAA compliance is paramount, ensuring the secure handling and privacy of sensitive health data. This foundational adherence to federal standards provides a strong starting point. Crucially, Hello Heart also demonstrates an adaptability to emerging state-level requirements. While specific state bills may introduce new nuances, a robust internal compliance program, built on strong data governance principles and a commitment to transparency, allows for more agile adaptation. This includes conducting regular privacy impact assessments, ensuring clear user consent mechanisms, and building AI models that prioritize fairness and minimize bias. Their strategy is not merely reactive but forward-looking, anticipating increased scrutiny and embedding responsible AI principles from inception. This proactive stance significantly de-risks their operations as regulatory scrutiny intensifies, making them an attractive partner for health plans seeking reliable and compliant digital health solutions.

The Road Ahead: Accelerating State Laws and the Investment Landscape

The trend of accelerating state-level AI legislation in healthcare is unlikely to abate in the near future. As AI technologies become more pervasive and sophisticated, public and political pressure for oversight will only grow. Policymakers, responding to concerns about algorithmic bias, data privacy, and accountability, will continue to propose and enact new laws. For health plan executives, this means that the strategic integration of AI cannot be divorced from a comprehensive regulatory intelligence function. Understanding which companies are building for multi-jurisdictional compliance, rather than merely federal adherence, will be a critical differentiator. Investment trends will increasingly favor companies that demonstrate not only technological prowess but also a robust and adaptable regulatory strategy. The cost of non-compliance, both in terms of fines and reputational damage, will become increasingly significant. Looking ahead to 2026 and beyond, the healthcare AI trends will be heavily shaped by this regulatory evolution. While the promise of AI to transform healthcare remains immense, unlocking that potential will depend on the industry’s ability to build and deploy these technologies responsibly and compliantly across a diverse and dynamic regulatory terrain. Companies that treat regulatory intelligence as a core strategic asset, much like their technological IP, will be the ones best positioned to benefit and drive meaningful change in patient care.